Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 8/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | S100A9 | P06702 | 2/20 | 0.36 |
| ▸ | MASP2 | O00187 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23479301 | 0.80 | DAO (0.46) | DAODYRK1AGRIN2DGRIN3BGRIN1 | |
| SCHEMBL7474417 | 0.78 | DAO (0.52) | DAODYRK1AGRIN2DGRIN3BGRIN1 | |
| SCHEMBL22185887 | 0.77 | MCL1 (0.55) | DAOGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL15782179 | 0.76 | DAO (0.54) | DAOGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL2056421 | 0.76 | GRIN2D (0.41) | DAOGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL10242711 | 0.74 | GRIN2D (0.40) | DAOGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL17546137 | 0.74 | ERCC1 (0.52) | DAOGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL4705062 | 0.74 | DYRK1A (0.51) | DAODYRK1A | |
| SCHEMBL8264421 | 0.73 | — | — | |
| SCHEMBL4649101 | 0.72 | GRIN2D (0.35) | DAODYRK1AGRIN2DGRIN3BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024138042-A1 | ALPHA4 BETA7 INTEGRIN ANTAGONISTS AND USES THEREOF | XINTHERA, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-11661418-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-05-30 | — | — | US | disclosed |
| US-20210171512-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2021-06-10 | — | — | US | disclosed |
| EP-3272754-B1 | IMIDAZOPYRROLIDINONE COMPOUNDS | NOVARTIS AG (CH) | 2019-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171512-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | DAO 3003/4885DYRK1A 3476/4885GRIN2D 2619/4885 |
| US-11661418-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | DAO 3003/4885DYRK1A 3476/4885GRIN2D 2619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.